Sam Lubner is an Oncology physician affiliated with University of Wisconsin–Madison. OpenAlex indexes 138 publications with 3,789 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 Highland Ave
Madison, WI 537920001
Telephone
608-265-1700Provider last certified this registry record 30 Dec 2020.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ipsen Biopharmaceuticals, IncProgram year20221 payment
- Lilly USA, LLCProgram year20221 payment
- Servier Pharmaceuticals LLCProgram year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
50.2%Opioid Agonist33.3%Oxycodone Hcl100%Part D≥15 patientsPhenothiazine10.9%Prochlorperazine Maleate100%Part D≥11 patients+ 1 more class in this area
Cancer & immunology
22.9%Kinase inhibitor22.9%Imatinib Mesylate100%Part D<11 patientsMetabolism & gastrointestinal
18.9%Serotonin-3 Receptor Antagonist18.9%Ondansetron Hcl100%Part D≥21 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity
Scientific Reports
2025 - Understanding futility in pancreaticoduodenectomy: Insights from a national cohort
Journal of Surgical Oncology
2024 - Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice
Journal of Clinical Oncology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
William Busse, MD
University of Wisconsin–Madison
David Andes, MD
University of Wisconsin–Madison
Neil Binkley, MD
University of Wisconsin–Madison
Robert Lemanske, MD
University of Wisconsin–Madison
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”